Overview
A Single-Dose Study in Normal Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of STX107
Status:
Completed
Completed
Trial end date:
2010-02-01
2010-02-01
Target enrollment:
0
0
Participant gender:
Male
Male
Summary
The objectives of this study are to determine the safety and tolerability of single oral doses of STX107 and to determine basic pharmacokinetic (PK) parameters following single oral doses of STX107 when administered via an oral suspensionPhase:
Phase 1Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Seaside Therapeutics, Inc.Collaborator:
National Institutes of Health (NIH)
Criteria
Inclusion Criteria:- Normal, healthy males 18-50 years old, inclusive.
- Able to comprehend and willing to sign an Informed Consent Form (ICF).
Exclusion Criteria:
Significant history or clinical manifestation of any significant metabolic, allergic,
dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal,
neurological, or psychiatric disorder (as determined by the Investigator).